Time tO last ChemotherApy and death in ovaRian cancEr patients: TO CARE/MITO 42 study, a retrospective analysis of italian MITO centers
IntroductionThe European Society for Medical Oncology (ESMO) 2021 Guidelines contraindicate the administration of chemotherapy in the last month of patients’ life. The main objective of this multicenter observational retrospective study was to calculate the time elapsed between the date of the last...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1641758/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849395869868097536 |
|---|---|
| author | Giulia Scotto Anna Galatà Robert Fruscio Robert Fruscio Giulia Besana Fabio Landoni Fabio Landoni Luca Sgro Alessandra Testi Fulvio Borella Gennaro Cormio Gennaro Cormio Mariangela Gianciotta Mariangela Gianciotta Francesca Arezzo Francesca Arezzo Brigida Anna Maiorano Alessandra Baldoni Marinella Destefanis Jole Ventriglia Sandro Pignata Rita Chiari Maria Carmen Azzolina Ivano Raimondo Ivano Raimondo Margherita Turinetto Valentina Tuninetti Massimo Di Maio Giorgio Valabrega |
| author_facet | Giulia Scotto Anna Galatà Robert Fruscio Robert Fruscio Giulia Besana Fabio Landoni Fabio Landoni Luca Sgro Alessandra Testi Fulvio Borella Gennaro Cormio Gennaro Cormio Mariangela Gianciotta Mariangela Gianciotta Francesca Arezzo Francesca Arezzo Brigida Anna Maiorano Alessandra Baldoni Marinella Destefanis Jole Ventriglia Sandro Pignata Rita Chiari Maria Carmen Azzolina Ivano Raimondo Ivano Raimondo Margherita Turinetto Valentina Tuninetti Massimo Di Maio Giorgio Valabrega |
| author_sort | Giulia Scotto |
| collection | DOAJ |
| description | IntroductionThe European Society for Medical Oncology (ESMO) 2021 Guidelines contraindicate the administration of chemotherapy in the last month of patients’ life. The main objective of this multicenter observational retrospective study was to calculate the time elapsed between the date of the last chemotherapy and the date of death of patients with ovarian cancer. The secondary objectives were to identify any factors associated with a greater probability of receiving chemotherapy in the end of life.MethodsOvarian cancer patients operated between 2010 and 2020 in the participant Italian centers were enrolled. Only deceased patients whose date of death and date of last chemotherapy were known were included.Results603 women from 10 Italian centers were included. One patient out of four (25.7%) received chemotherapy in the last month of life. The median survival from the last chemotherapy was 66 days. Patients with a neutrophil/lymphocyte ratio ≥5, with high C-reactive protein at the start of the last line and patients dying in hospital compared to hospice/palliative care at home were more likely to undergo chemotherapy at the end of life (p<0.001, p=0.05 and p<0.001 respectively). Being treated in Northern Italy reduces the chance of receiving chemotherapy at the end of life in comparison with Center-South (p<0.001), as well as being enrolled in at least one clinical protocol (p=0.027).DiscussionThe TO CARE/MITO 42 study is a snapshot of the Italian practice in which there are still disparities in the treatment of patients at the end of life. A prospective observational study could provide useful elements for early identification of patients who would not benefit from a further line. |
| format | Article |
| id | doaj-art-b1cde4e1abe64008a2136ab06db5f950 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-b1cde4e1abe64008a2136ab06db5f9502025-08-20T03:39:29ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-08-011510.3389/fonc.2025.16417581641758Time tO last ChemotherApy and death in ovaRian cancEr patients: TO CARE/MITO 42 study, a retrospective analysis of italian MITO centersGiulia Scotto0Anna Galatà1Robert Fruscio2Robert Fruscio3Giulia Besana4Fabio Landoni5Fabio Landoni6Luca Sgro7Alessandra Testi8Fulvio Borella9Gennaro Cormio10Gennaro Cormio11Mariangela Gianciotta12Mariangela Gianciotta13Francesca Arezzo14Francesca Arezzo15Brigida Anna Maiorano16Alessandra Baldoni17Marinella Destefanis18Jole Ventriglia19Sandro Pignata20Rita Chiari21Maria Carmen Azzolina22Ivano Raimondo23Ivano Raimondo24Margherita Turinetto25Valentina Tuninetti26Massimo Di Maio27Giorgio Valabrega28Medical Oncology, ASL TO3 Ospedale degli Infermi, Rivoli, Torino, ItalyDepartment of Oncology, University of Turin, Turin, ItalyUO Gynecology, Fondazione IRCCS San Gerardo, Monza, ItalyDepartment of Medicine and Surgery, University of Milan-Bicocca, Milan, ItalyDepartment of Medicine and Surgery, University of Milan-Bicocca, Milan, ItalyUO Gynecology, Fondazione IRCCS San Gerardo, Monza, ItalyDepartment of Medicine and Surgery, University of Milan-Bicocca, Milan, ItalyObstetrics and Gynaecology Unit, Umberto I Hospital, Department of Surgical Sciences, School of Medicine, University of Turin, Turin, ItalyObstetrics and Gynaecology Unit, Umberto I Hospital, Department of Surgical Sciences, School of Medicine, University of Turin, Turin, ItalyGynecology and Obstetrics Unit 1, Department of Surgical Sciences, City of Health and Science University Hospital, University of Turin, Turin, ItalyGynecologic Oncology Unit, IRCCS Istituto Tumori “Giovanni Paolo II”, Bari, ItalyInterdisciplinar Department of Medicine, University of Bari “Aldo Moro”, Bari, ItalyGynecologic Oncology Unit, IRCCS Istituto Tumori “Giovanni Paolo II”, Bari, ItalyInterdisciplinar Department of Medicine, University of Bari “Aldo Moro”, Bari, ItalyGynecologic Oncology Unit, IRCCS Istituto Tumori “Giovanni Paolo II”, Bari, ItalyDepartment of Precision and Regenerative Medicine - DiMePRe-J, University of Bari “Aldo Moro”, Bari, Italy0Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy1Oncology and Hematology Department, Mirano AULSS3 Serenissima, Mirano, Italy2Dipartimento Chirurgico ASO S. Croce e Carle Cuneo, Cuneo, Italy3Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Naples, Italy3Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Naples, Italy4UOC ONCOLOGIA AST Pesaro Urbino, Pesaro Urbino, Italy5AO Ordine Mauriziano, Torino, Italy6School in Biomedical Sciences, University of Sassari, Sassari, Italy7Department of Gynecology, Mater Olbia Hospital, Olbia, ItalyDepartment of Oncology, University of Turin, Turin, Italy8Department of Oncology, University of Turin, Medical Oncology, Ordine Mauriziano Hospital, Turin, Italy9Department of Oncology, University of Turin, AOU Città della Salute e della Scienza di Torino, Turin, Italy8Department of Oncology, University of Turin, Medical Oncology, Ordine Mauriziano Hospital, Turin, ItalyIntroductionThe European Society for Medical Oncology (ESMO) 2021 Guidelines contraindicate the administration of chemotherapy in the last month of patients’ life. The main objective of this multicenter observational retrospective study was to calculate the time elapsed between the date of the last chemotherapy and the date of death of patients with ovarian cancer. The secondary objectives were to identify any factors associated with a greater probability of receiving chemotherapy in the end of life.MethodsOvarian cancer patients operated between 2010 and 2020 in the participant Italian centers were enrolled. Only deceased patients whose date of death and date of last chemotherapy were known were included.Results603 women from 10 Italian centers were included. One patient out of four (25.7%) received chemotherapy in the last month of life. The median survival from the last chemotherapy was 66 days. Patients with a neutrophil/lymphocyte ratio ≥5, with high C-reactive protein at the start of the last line and patients dying in hospital compared to hospice/palliative care at home were more likely to undergo chemotherapy at the end of life (p<0.001, p=0.05 and p<0.001 respectively). Being treated in Northern Italy reduces the chance of receiving chemotherapy at the end of life in comparison with Center-South (p<0.001), as well as being enrolled in at least one clinical protocol (p=0.027).DiscussionThe TO CARE/MITO 42 study is a snapshot of the Italian practice in which there are still disparities in the treatment of patients at the end of life. A prospective observational study could provide useful elements for early identification of patients who would not benefit from a further line.https://www.frontiersin.org/articles/10.3389/fonc.2025.1641758/fullovarian cancerchemotherapyend of lifequality of lifegynecologic cancer |
| spellingShingle | Giulia Scotto Anna Galatà Robert Fruscio Robert Fruscio Giulia Besana Fabio Landoni Fabio Landoni Luca Sgro Alessandra Testi Fulvio Borella Gennaro Cormio Gennaro Cormio Mariangela Gianciotta Mariangela Gianciotta Francesca Arezzo Francesca Arezzo Brigida Anna Maiorano Alessandra Baldoni Marinella Destefanis Jole Ventriglia Sandro Pignata Rita Chiari Maria Carmen Azzolina Ivano Raimondo Ivano Raimondo Margherita Turinetto Valentina Tuninetti Massimo Di Maio Giorgio Valabrega Time tO last ChemotherApy and death in ovaRian cancEr patients: TO CARE/MITO 42 study, a retrospective analysis of italian MITO centers Frontiers in Oncology ovarian cancer chemotherapy end of life quality of life gynecologic cancer |
| title | Time tO last ChemotherApy and death in ovaRian cancEr patients: TO CARE/MITO 42 study, a retrospective analysis of italian MITO centers |
| title_full | Time tO last ChemotherApy and death in ovaRian cancEr patients: TO CARE/MITO 42 study, a retrospective analysis of italian MITO centers |
| title_fullStr | Time tO last ChemotherApy and death in ovaRian cancEr patients: TO CARE/MITO 42 study, a retrospective analysis of italian MITO centers |
| title_full_unstemmed | Time tO last ChemotherApy and death in ovaRian cancEr patients: TO CARE/MITO 42 study, a retrospective analysis of italian MITO centers |
| title_short | Time tO last ChemotherApy and death in ovaRian cancEr patients: TO CARE/MITO 42 study, a retrospective analysis of italian MITO centers |
| title_sort | time to last chemotherapy and death in ovarian cancer patients to care mito 42 study a retrospective analysis of italian mito centers |
| topic | ovarian cancer chemotherapy end of life quality of life gynecologic cancer |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1641758/full |
| work_keys_str_mv | AT giuliascotto timetolastchemotherapyanddeathinovariancancerpatientstocaremito42studyaretrospectiveanalysisofitalianmitocenters AT annagalata timetolastchemotherapyanddeathinovariancancerpatientstocaremito42studyaretrospectiveanalysisofitalianmitocenters AT robertfruscio timetolastchemotherapyanddeathinovariancancerpatientstocaremito42studyaretrospectiveanalysisofitalianmitocenters AT robertfruscio timetolastchemotherapyanddeathinovariancancerpatientstocaremito42studyaretrospectiveanalysisofitalianmitocenters AT giuliabesana timetolastchemotherapyanddeathinovariancancerpatientstocaremito42studyaretrospectiveanalysisofitalianmitocenters AT fabiolandoni timetolastchemotherapyanddeathinovariancancerpatientstocaremito42studyaretrospectiveanalysisofitalianmitocenters AT fabiolandoni timetolastchemotherapyanddeathinovariancancerpatientstocaremito42studyaretrospectiveanalysisofitalianmitocenters AT lucasgro timetolastchemotherapyanddeathinovariancancerpatientstocaremito42studyaretrospectiveanalysisofitalianmitocenters AT alessandratesti timetolastchemotherapyanddeathinovariancancerpatientstocaremito42studyaretrospectiveanalysisofitalianmitocenters AT fulvioborella timetolastchemotherapyanddeathinovariancancerpatientstocaremito42studyaretrospectiveanalysisofitalianmitocenters AT gennarocormio timetolastchemotherapyanddeathinovariancancerpatientstocaremito42studyaretrospectiveanalysisofitalianmitocenters AT gennarocormio timetolastchemotherapyanddeathinovariancancerpatientstocaremito42studyaretrospectiveanalysisofitalianmitocenters AT mariangelagianciotta timetolastchemotherapyanddeathinovariancancerpatientstocaremito42studyaretrospectiveanalysisofitalianmitocenters AT mariangelagianciotta timetolastchemotherapyanddeathinovariancancerpatientstocaremito42studyaretrospectiveanalysisofitalianmitocenters AT francescaarezzo timetolastchemotherapyanddeathinovariancancerpatientstocaremito42studyaretrospectiveanalysisofitalianmitocenters AT francescaarezzo timetolastchemotherapyanddeathinovariancancerpatientstocaremito42studyaretrospectiveanalysisofitalianmitocenters AT brigidaannamaiorano timetolastchemotherapyanddeathinovariancancerpatientstocaremito42studyaretrospectiveanalysisofitalianmitocenters AT alessandrabaldoni timetolastchemotherapyanddeathinovariancancerpatientstocaremito42studyaretrospectiveanalysisofitalianmitocenters AT marinelladestefanis timetolastchemotherapyanddeathinovariancancerpatientstocaremito42studyaretrospectiveanalysisofitalianmitocenters AT joleventriglia timetolastchemotherapyanddeathinovariancancerpatientstocaremito42studyaretrospectiveanalysisofitalianmitocenters AT sandropignata timetolastchemotherapyanddeathinovariancancerpatientstocaremito42studyaretrospectiveanalysisofitalianmitocenters AT ritachiari timetolastchemotherapyanddeathinovariancancerpatientstocaremito42studyaretrospectiveanalysisofitalianmitocenters AT mariacarmenazzolina timetolastchemotherapyanddeathinovariancancerpatientstocaremito42studyaretrospectiveanalysisofitalianmitocenters AT ivanoraimondo timetolastchemotherapyanddeathinovariancancerpatientstocaremito42studyaretrospectiveanalysisofitalianmitocenters AT ivanoraimondo timetolastchemotherapyanddeathinovariancancerpatientstocaremito42studyaretrospectiveanalysisofitalianmitocenters AT margheritaturinetto timetolastchemotherapyanddeathinovariancancerpatientstocaremito42studyaretrospectiveanalysisofitalianmitocenters AT valentinatuninetti timetolastchemotherapyanddeathinovariancancerpatientstocaremito42studyaretrospectiveanalysisofitalianmitocenters AT massimodimaio timetolastchemotherapyanddeathinovariancancerpatientstocaremito42studyaretrospectiveanalysisofitalianmitocenters AT giorgiovalabrega timetolastchemotherapyanddeathinovariancancerpatientstocaremito42studyaretrospectiveanalysisofitalianmitocenters |